具有生存结果和预测生物标志物错误分类的调整的两阶段适应性丰富设计
Yanping Chen1, Yong Lin2, Shou-En Lu2
1Biostatistics and Data Management, Regeneron Pharmaceuticals, Baskin Ridge, New Jersey, USA.
Statistics in biopharmaceutical research
|October 20, 2025
概括
本研究引入了使用生物标志物改进治疗效果评估的两阶段临床试验设计. 该方法考虑了生物标志物测定错误,提高了对生存结果的试验效率.
科学领域:
- 生物统计学 生物统计学
- 临床试验设计 临床试验设计
- 翻译医学是一种翻译医学.
背景情况:
- 生物标志物丰富策略提高了临床试验的效率.
- 生物标志物分类中的测定错误使试验设计复杂化.
- 生存结果需要专门的统计方法.
研究的目的:
- 为生存结果提出一个两阶段的丰富临床试验设计.
- 为了应对潜在的生物标志物测试错误所带来的挑战.
- 提高治疗效果评估的效率和准确性.
主要方法:
- 一个两阶段的设计,中间分析和徒劳性标准.
- 在第一阶段,基于生物标志物状态的分层随机化.
- 开发调整后的逻辑等级统计,考虑到敏感性和特异性.
- 控制I型错误率的方法,考虑统计数据之间的相关性.
主要成果:
- 拟议的设计允许在第二阶段基于中间分析进行丰富.
- 调整后的日志等级统计提供了一个强大的方法来处理生物标志物错误分类.
- 通过仔细的统计调整来保持I型错误控制.
- 提供R代码用于实际实施和样本大小计算.
结论:
- 新的两阶段设计为生物标志物引导的试验提供了灵活和高效的方法,具有生存终点.
- 该方法有效地管理生物标志物测试的不准确性.
- 这种方法适用于各种治疗领域,包括非小细胞肺癌的免疫治疗.
更多相关视频
相关概念视频
Assumptions of Survival Analysis
391
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
391
Comparing the Survival Analysis of Two or More Groups
551
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
551
Kaplan-Meier Approach
566
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
566
Strategies for Assessing and Addressing Confounding
359
Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
359
Censoring Survival Data
520
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
520
Cancer Survival Analysis
645
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645


